+-----------------------------------------------------------------------------------------------------------------------+
| Brand Card (highlight lime green, title fs 60px, description fs 24px, ctanumber none, ctatype button, ctacolor light, |
| ctastyle primary, ctaselection link, ctatarget sametab, ctaexitinterstitial select, ctatype button two, ctacolor |
| light two, ctastyle primary two, ctaselection link two, ctatarget sametab two, ctaexitinterstitial select two, label |
| fs 14px, element jump links, ctanumber one bottom, ctatype button three, ctacolor light three, ctastyle primary |
| three, ctaselection link three, ctatarget sametab three, ctaexitinterstitial select three, ctatype button four, |
| ctacolor light four, ctastyle primary four, ctaselection link four, ctatarget sametab four, ctaexitinterstitial |
| select four, ctanumber quicklink one, ctacolor light five, ctastyle primary five, ctaselection quicklink link, |
| ctatarget quicklink sametab, ctaexitinterstitial quicklink select, ctacolor light six, ctastyle primary six, |
| ctaselection quicklink link two, ctatarget quicklink sametab two, ctaexitinterstitial quicklink select two, ctacolor |
| light seven, ctastyle primary seven, ctaselection quicklink link three, ctatarget quicklink sametab three, |
| ctaexitinterstitial quicklink select three) |
+-----------------------------------------------------------------------------------------------------------------------+
| ![2.5 mg Zepbound (tirzepatide) injection pen, single-dose vial and KwikPen® for single-patient use][image0] |
| |
| ![2.5 mg Zepbound (tirzepatide) injection pen, single-dose vial and KwikPen® for single-patient use][image1] |
+-----------------------------------------------------------------------------------------------------------------------+
| This site is intended for U.S. Healthcare Providers |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| # **Explore Zepbound®***(tirzepatide) injection*
**Dosing** |
+-----------------------------------------------------------------------------------------------------------------------+
| true |
+-----------------------------------------------------------------------------------------------------------------------+
| Learn about Zepbound formulations available in a single-dose Pen, single-dose Vial, and KwikPen® for single-patient |
| use.\ |
| \ |
| 2.5 mg is a starting dose and is not an approved maintenance dose. |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| true |
+-----------------------------------------------------------------------------------------------------------------------+
| on this page |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| Dosing options |
| |
| Dosing Options |
| |
| DosingOptions |
+-----------------------------------------------------------------------------------------------------------------------+
| Dosing schedule |
| |
| Dosing Schedule |
| |
| DosingSchedule |
+-----------------------------------------------------------------------------------------------------------------------+
| Mitigating gastrointestinal side effects |
| |
| Mitigating Gastrointestinal Side Effects |
| |
| MitigatingSideEffects |
+-----------------------------------------------------------------------------------------------------------------------+
| Missed dose |
| |
| Missed Dose |
| |
| MissedDose |
+-----------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Section Metadata |
+-----------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| backgroundOption | image |
+-----------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| backgroundColor | primary |
+-----------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| image | [Gradient background](https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:c780e3c2-c1c7-41db-9de2-83fa82710266/as/BG_03-2.avif?assetname=BG_03\+2.png) |
+-----------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| textColor | auto |
+-----------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
---
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, large one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment center, description fs 60px, ctanumber one, ctatype button, ctacolor light, ctastyle |
| primary, ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light |
| two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+-------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------+
| ## EXPLORE DOSING |
+-------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------+
| **Explore dosing options for Zepbound** |
+-------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------+
| |
+-------------------------------------------------------------------------------------------------------------------+
+-----------------------------------------------------+
| Section Metadata |
+-----------------------------------+-----------------+
| text | DosingOptions |
+-----------------------------------+-----------------+
| backgroundOption | color |
+-----------------------------------+-----------------+
| backgroundColor | background-none |
+-----------------------------------+-----------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+-----------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+-----------------+
| textColor | auto |
+-----------------------------------+-----------------+
| additionalPadding | narrow |
+-----------------------------------+-----------------+
---
+------------------------------------------------------------------------+
| Tabs |
+------------------------------------------------------------------------+
| |
+-------------------------------------------+----------------------------+
| Zepbound Single-Dose Pen | zepbound\_pen\_section |
+-------------------------------------------+----------------------------+
| Zepbound Single-Dose Vial | zepbound\_vial\_section |
+-------------------------------------------+----------------------------+
| Zepbound® KwikPen® for Single-Patient Use | zepbound\_kwikpen\_section |
+-------------------------------------------+----------------------------+
+------------------------------------------+
| Section Metadata |
+---------+--------------------------------+
| style | tabs-container-background-none |
+---------+--------------------------------+
---
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Two Column With Image (imageplacement left, mediatype icon, textplacement top, title fs 36px, ctanumber two, ctaplacement left, background color none, ctatype button, ctacolor light, ctastyle primary, ctaselection link, ctatarget sametab, ctaexitinterstitial select, |
| ctatype button two, ctacolor light two, ctastyle primary two, ctaselection link two, ctatarget sametab two, ctaexitinterstitial select two) |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| ![Zepbound (tirzepatide) injection pen][image2] |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 2.5 mg is for treatment initiation only |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Zepbound Single-Dose Pen** |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg\ |
| \ |
| Share the savings card for the Single-Dose Pen with your eligible, commercially insured patients. |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| [Share the Zepbound savings card](/savings "Share the Zepbound Savings Card") |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| [Prescribe via LillyDirect®](https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:544069d2-cf3d-4043-91a6-f63784285485/renditions/original/as/zepbound_Vial_Guide.pdf?assetname=zepbound_Vial_Guide.pdf "Learn how to prescribe via LillyDirect") |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, |
| ctatype button two, ctacolor light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Governmental beneficiaries excluded, terms and conditions apply.** [Review full terms and conditions](/savings/terms-and-conditions "Review full terms and conditions") |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
+------------------------------------------------------------+
| Section Metadata |
+-----------------------------------+------------------------+
| text | zepbound\_pen\_section |
+-----------------------------------+------------------------+
| backgroundOption | color |
+-----------------------------------+------------------------+
| backgroundColor | background-none |
+-----------------------------------+------------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+------------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+------------------------+
| textColor | auto |
+-----------------------------------+------------------------+
---
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Two Column With Image (imageplacement left, mediatype icon, textplacement top, title fs 36px, ctanumber one, ctaplacement left, background color none, ctatype button, ctacolor light, ctastyle primary, ctaselection link, ctatarget sametab, ctaexitinterstitial select, ctatype button two, ctacolor |
| light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| ![Zepbound (tirzepatide) injection KwikPen][image3] |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 2.5 MG IS FOR TREATMENT INITIATION ONLY |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Zepbound® KwikPen® for Single-Patient Use** |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (4 doses per KwikPen)\ |
| \ |
| For patients, regardless of insurance, including Medicare, Medicaid, and no insurance. Terms apply. Taxes and fees may apply. |
| |
| **\ |
| LillyDirect®** |
| |
| Available through LillyDirect® Pharmacy with automatic self-pay pricing applied. |
| |
| **Retail Pharmacies** |
| |
| If patient chooses to fulfill their KwikPen prescription at a retail pharmacy, they can use the self-pay savings card at **[zepbound.com/savings](/savings "Savings")** |
| |
| **\ |
| Self-pay only.** Eligibility required, terms and conditions apply. Savings subject to monthly and annual limits. Month is defined as 28-days and 1 single-patient-use KwikPen. Card eligibility and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without |
| notice and for any reason. **PROGRAM IS NOT INSURANCE.** Review full terms and conditions at: [https://zepbound.lilly.com/savings#terms-and-conditions-2](/savings/terms-and-conditions-kwikpen-self-pay "Terms and Conditions") |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| [Prescribe via LillyDirect®](https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:544069d2-cf3d-4043-91a6-f63784285485/renditions/original/as/zepbound_Vial_Guide.pdf?assetname=zepbound_Vial_Guide.pdf "Learn how to prescribe via LillyDirect") |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------------+
| Section Metadata |
+-----------------------------------+----------------------------+
| text | zepbound\_kwikpen\_section |
+-----------------------------------+----------------------------+
| backgroundOption | color |
+-----------------------------------+----------------------------+
| backgroundColor | background-none |
+-----------------------------------+----------------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+----------------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+----------------------------+
| textColor | auto |
+-----------------------------------+----------------------------+
---
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Two Column With Image (imageplacement left, mediatype icon, textplacement top, title fs 36px, ctanumber one, ctaplacement left, background color none, ctatype button, ctacolor light, ctastyle primary, ctaselection link, ctatarget newtab, ctaexitinterstitial select, |
| ctatype button two, ctacolor light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| ![Zepbound (tirzepatide) injection vial][image4] |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 2.5 mg is for treatment initiation only |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Zepbound Single-Dose Vial** |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg\ |
| \ |
| For patients, regardless of insurance, including Medicare, Medicaid, and no insurance\ |
| \ |
| Available exclusively through LillyDirect® Pharmacy. Terms apply. Taxes and fees may apply. |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| [Prescribe via LillyDirect®](https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:544069d2-cf3d-4043-91a6-f63784285485/renditions/original/as/zepbound_Vial_Guide.pdf?assetname=zepbound_Vial_Guide.pdf "Learn how to Prescribe via LillyDirect®") |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
+-------------------------------------------------------------+
| Section Metadata |
+-----------------------------------+-------------------------+
| text | zepbound\_vial\_section |
+-----------------------------------+-------------------------+
| backgroundOption | color |
+-----------------------------------+-------------------------+
| backgroundColor | background-none |
+-----------------------------------+-------------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+-------------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+-------------------------+
| textColor | auto |
+-----------------------------------+-------------------------+
---
+------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign center, highlight color primary, title fs 36px, titlestyle ringside, ctastyle secondary, |
| ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| ### Have questions about the cost and coverage for Zepbound? |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| [See the savings](/hcp/coverage-savings "See how patients can save with zepbound") |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
+------------------------------------------------------+
| Section Metadata |
+-----------------------------------+------------------+
| backgroundOption | color |
+-----------------------------------+------------------+
| backgroundColor | background-muted |
+-----------------------------------+------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+------------------+
| textColor | auto |
+-----------------------------------+------------------+
| additionalPadding | narrow |
+-----------------------------------+------------------+
| additionalMargin | narrow |
+-----------------------------------+------------------+
| roundedBorders | true |
+-----------------------------------+------------------+
---
+--------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment center, description font color none, description fs 60px, ctanumber one, ctatype button, |
| ctacolor light, ctastyle primary, ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, ctatype |
| button two, ctacolor light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| ## DOSING SCHEDULE |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| ### **Starting and continuing Zepbound** |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------+
| Spacer And Divider (spacer, medium, contrast, small one) |
+----------------------------------------------------------+
| |
+----------------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign center, highlight color primary, titlestyle ringside, description fs 24px, ctastyle primary, |
| ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| A once-weekly, subcutaneous injection1 |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Image Block (description fs 16px) |
+-----------------------------------------------------------------------------------------------------------------------+
| ![Start and continue once-weekly Zepbound][image5] |
+-----------------------------------------------------------------------------------------------------------------------+
| ![Start and continue once-weekly Zepbound][image6] |
+-----------------------------------------------------------------------------------------------------------------------+
| Show Description |
| |
| Image depicting the dose escalation of Zepbound. Starting dose is 2.5 mg once weekly for 4 weeks. Continue to 5 mg |
| dose once weekly for at least 4 weeks. The dose can be increased to 7.5 mg once weekly for at least 4 weeks, followed |
| by 10 mg maintenance dose once weekly for at least 4 weeks, then 12.5 mg once weekly for at least 4 weeks, and |
| finally 15 mg maintenance dose once weekly as the maximum dose. 5 mg is a recommended maintenance dose for weight |
| reduction indication only; 10 mg or 15 mg are recommended maintenance doses for all approved indications. |
+-----------------------------------------------------------------------------------------------------------------------+
| true |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-------------------------------------------------------+
| Section Metadata |
+-----------------------------------+-------------------+
| text | DosingSchedule |
+-----------------------------------+-------------------+
| backgroundOption | color |
+-----------------------------------+-------------------+
| backgroundColor | background-custom |
+-----------------------------------+-------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+-------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+-------------------+
| textColor | auto |
+-----------------------------------+-------------------+
| additionalPadding | narrow |
+-----------------------------------+-------------------+
---
+-----------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, description fs 20px, ctanumber one, ctatype button, ctacolor light, ctastyle primary, |
| ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, |
| ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| For adults with obesity, or with overweight with at least 1 weight-related comorbidity in combination with a |
| reduced-calorie diet and increased physical activity.1 |
| |
| For adults with moderate-to-severe OSA and obesity in combination with a reduced-calorie diet and increased physical |
| activity.1 |
| |
| The 2.5 mg dosage is for treatment initiation and is not intended to be a maintenance dose.1 |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+--------------+
| Column Break |
+--------------+
| |
+--------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, description fs 20px, ctanumber one, ctatype button, ctacolor light, ctastyle primary, |
| ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, |
| ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| Recommended maintenance dosages are 5 mg, 10 mg, or 15 mg for weight reduction and 10 mg or 15 mg for |
| moderate-to-severe OSA and obesity1 |
| |
| - Initiate with the 2.5 mg dose |
| - After 4 weeks, increase to the 5 mg dose |
| - You can continue to increase the dose by 2.5 mg increments after at least 4 weeks on the current dose. The maximum |
| dose is 15 mg |
| - Consider treatment response and tolerability when selecting maintenance dosage. If not tolerated, consider a lower |
| maintenance dosage |
+-----------------------------------------------------------------------------------------------------------------------+
| OSA=obstructive sleep apnea. |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------------+
| Section Metadata |
+-----------------------------------+----------------------------+
| backgroundOption | color |
+-----------------------------------+----------------------------+
| backgroundColor | background-custom |
+-----------------------------------+----------------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+----------------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+----------------------------+
| textColor | auto |
+-----------------------------------+----------------------------+
| style | two-col-50-50, inner-color |
+-----------------------------------+----------------------------+
| additionalPadding | none |
+-----------------------------------+----------------------------+
| additionalMargin | none |
+-----------------------------------+----------------------------+
---
+----------------------------------------------------------------------------------------------------+
| Horizontal Numeric Tile (variation 2, sectiondescription fs 60px) |
+----------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------+
| **Ways you can help your\ |
| patients:** |
+----------------------------------------------------------------------------------------------------+
| |
+----------------+---------------------+----------------+--------------------------------------------+
| #### **01** | numeric-tile, | #### Remind | Patients that Zepbound is |
| | title-fs-36px, | | administered once weekly.1 |
| | texttitle-fs-32px, | | |
| | description-fs-20px | | |
+----------------+---------------------+----------------+--------------------------------------------+
| #### **02** | numeric-tile, | #### Advise | Patients to read the Instructions for |
| | title-fs-36px, | | Use.2 |
| | texttitle-fs-32px, | | |
| | description-fs-20px | | |
+----------------+---------------------+----------------+--------------------------------------------+
| #### **03** | numeric-tile, | #### Consider | Having patients administer the first |
| | title-fs-36px, | | dose in the office. |
| | texttitle-fs-32px, | | |
| | description-fs-20px | | |
+----------------+---------------------+----------------+--------------------------------------------+
| #### **04** | numeric-tile, | #### Discuss | Safety profile and that Zepbound may |
| | title-fs-36px, | | cause some side effects.\* For |
| | texttitle-fs-32px, | | example, patients may experience |
| | description-fs-20px | | nausea, diarrhea, or vomiting.1 |
+----------------+---------------------+----------------+--------------------------------------------+
+-------------------------------------------------------+
| Section Metadata |
+-----------------------------------+-------------------+
| backgroundOption | color |
+-----------------------------------+-------------------+
| backgroundColor | background-custom |
+-----------------------------------+-------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+-------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+-------------------+
| textColor | auto |
+-----------------------------------+-------------------+
| additionalPadding | narrow |
+-----------------------------------+-------------------+
---
+-----------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 36px, titlestyle ringside, description fs 20px, |
| ctastyle primary, ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| ### **Mitigate gastrointestinal side effects** |
+-----------------------------------------------------------------------------------------------------------------+
| In order to mitigate gastrointestinal side effects, patients may find it helpful to3-5: |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, small, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+------------------------------------------------------------------------------------------------------------------------------------+
| Icontile (columnconfig 2 col) |
+------------------------------------------------------------------------------------------------------------------------------------+
| |
+----+--------------------------------------+--------------------------------------+----------------------+-----------------+---+----+
| | ![Eating smaller meals icon][image7] | #### Eat smaller meals | tile, title-fs-28px, | Suggest that | | |
| | | | description-fs-16px, | they split 3 | | |
| | | | ctaselection-link | daily meals | | |
| | | | | into 4 or more | | |
| | | | | smaller meals | | |
+----+--------------------------------------+--------------------------------------+----------------------+-----------------+---+----+
| | ![feeling full icon][image8] | #### Stop eating when they feel full | tile, title-fs-28px | | | |
+----+--------------------------------------+--------------------------------------+----------------------+-----------------+---+----+
| | ![hamburger icon][image9] | #### Avoid fatty foods | tile, title-fs-28px | | | |
+----+--------------------------------------+--------------------------------------+----------------------+-----------------+---+----+
| | ![toast icon][image10] | #### Try eating bland foods | tile, title-fs-28px | | | |
+----+--------------------------------------+--------------------------------------+----------------------+-----------------+---+----+
| | ![medicin bottle icon][image11] | #### Drink plenty of water | tile, title-fs-28px, | Encourage | | |
| | | | description-fs-16px | patients to eat | | |
| | | | | healthy meals | | |
| | | | | to ensure they | | |
| | | | | meet their | | |
| | | | | needs for | | |
| | | | | protein, | | |
| | | | | micronutrients, | | |
| | | | | fiber, and | | |
| | | | | fluids. | | |
+----+--------------------------------------+--------------------------------------+----------------------+-----------------+---+----+
+---------------------------------------------------------+
| Spacer And Divider (spacer, small, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, small, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+--------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, footnote fs 16px, ctanumber one, ctatype button, ctacolor light, ctastyle primary, |
| ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, |
| ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| \*Side effects may vary and should be evaluated by the healthcare provider for appropriate management. |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------+
| Spacer And Divider (spacer, medium, contrast, small one) |
+----------------------------------------------------------+
| |
+----------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, small, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Icontile (columnconfig 2 col) |
+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----+-------------------------------+----------------------------------------------------+---------------------+-----------------------------------+---+----+
| | ![water bottle icon][image12] | #### Recommend switching to non-oral contraceptive | tile, | Recommend patients who | | |
| | | | title-fs-28px, | are using oral | | |
| | | | description-fs-16px | hormonal | | |
| | | | | contraceptives switch | | |
| | | | | to a non-oral | | |
| | | | | contraceptive method, | | |
| | | | | or add a barrier | | |
| | | | | method of | | |
| | | | | contraception, for 4 | | |
| | | | | weeks after initiation | | |
| | | | | with Zepbound and for | | |
| | | | | 4 weeks after each | | |
| | | | | dose escalation. Use | | |
| | | | | of Zepbound may reduce | | |
| | | | | the efficacy of oral | | |
| | | | | hormonal | | |
| | | | | contraceptives due to | | |
| | | | | delayed gastric | | |
| | | | | emptying. This delay | | |
| | | | | is largest after the | | |
| | | | | first dose and | | |
| | | | | diminishes over time.1 | | |
+----+-------------------------------+----------------------------------------------------+---------------------+-----------------------------------+---+----+
+-----------------------------------------------------------+
| Section Metadata |
+-----------------------------------+-----------------------+
| text | MitigatingSideEffects |
+-----------------------------------+-----------------------+
| backgroundOption | color |
+-----------------------------------+-----------------------+
| backgroundColor | background-custom |
+-----------------------------------+-----------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+-----------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+-----------------------+
| textColor | auto |
+-----------------------------------+-----------------------+
| additionalPadding | narrow |
+-----------------------------------+-----------------------+
---
+----------------------------------------------------------+
| Spacer And Divider (spacer, medium, contrast, small one) |
+----------------------------------------------------------+
| |
+----------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, small, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+--------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment center, description font color none, description fs 60px, ctanumber one, ctatype button, |
| ctacolor light, ctastyle primary, ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, ctatype |
| button two, ctacolor light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| DOSING SCHEDULE |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| ### **What happens if a dose is missed?** |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------+
| Spacer And Divider (spacer, medium, contrast, small one) |
+----------------------------------------------------------+
| |
+----------------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign center, highlight color primary, titlestyle ringside, description fs 24px, ctastyle primary, |
| ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| If a dose is missed, instruct patients to administer Zepbound as soon as possible within 4 days after the missed |
| dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled |
| day.1 |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------+
| Spacer And Divider (spacer, medium, contrast, small one) |
+----------------------------------------------------------+
| |
+----------------------------------------------------------+
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment center, description fs 20px, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, ctaexitinterstitial select, |
| ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| For adult patients with obesity (BMI of ≥30 kg/m2) or with overweight (BMI of ≥27 kg/m2) with at least 1 weight-related comorbidity.1 |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------+
| Image Block |
+-----------------------------------+
| ![dosing schedule image][image13] |
+-----------------------------------+
| ![dosing schedule image][image14] |
+-----------------------------------+
| |
+-----------------------------------+
| true |
+-----------------------------------+
| |
+-----------------------------------+
+----------------------------------------------------------+
| Spacer And Divider (divider, large, contrast, small one) |
+----------------------------------------------------------+
| |
+----------------------------------------------------------+
+------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, description font color none, description fs 16px, ctanumber one, ctatype button, |
| ctacolor light, ctastyle primary, ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, ctatype |
| button two, ctacolor light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+------------------------------------------------------------------------------------------------------------------+
| ![Shield with exclamation point inside][image15] |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
| |
+------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, title fs 16px, titlestyle ringside, description fs 16px, |
| ctastyle primary, ctacolor light, ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| **Select Important Safety Information** |
+----------------------------------------------------------------------------------------------------------------------+
| **Severe Gastrointestinal Adverse Reactions:** Use of Zepbound has been associated with gastrointestinal adverse |
| reactions, sometimes severe. In a pool of two Zepbound clinical trials (SURMOUNT-1 and SURMOUNT-2), severe |
| gastrointestinal adverse reactions were reported more frequently among patients receiving Zepbound (5 mg 1.7%, 10 mg |
| 2\.5%, 15 mg 3.1%) than placebo (1.0%). Similar rates of severe gastrointestinal adverse reactions were observed in |
| Zepbound clinical trials for weight reduction and in Zepbound clinical trials for obstructive sleep apnea (OSA). |
| Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. |
| Zepbound is not recommended in patients with severe gastroparesis. |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------+
| Spacer And Divider (spacer, medium, contrast, small one) |
+----------------------------------------------------------+
| |
+----------------------------------------------------------+
+-----------------------------------------------------+
| Section Metadata |
+-----------------------------------+-----------------+
| text | MissedDose |
+-----------------------------------+-----------------+
| backgroundOption | color |
+-----------------------------------+-----------------+
| backgroundColor | background-none |
+-----------------------------------+-----------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+-----------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+-----------------+
| textColor | auto |
+-----------------------------------+-----------------+
| additionalPadding | narrow |
+-----------------------------------+-----------------+
| additionalMargin | none |
+-----------------------------------+-----------------+
---
+----------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, title fs 48px, description fs 20px, ctanumber one, ctatype button, ctacolor light, |
| ctastyle secondary, ctaselection link, ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, ctatype |
| button two, ctacolor light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| **Helpful resources for you** |
+----------------------------------------------------------------------------------------------------------------------+
| Discover how you can help your patients by completing prior authorization, ordering a demo kit, or learning about a |
| savings card. |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| [Explore all resources](/hcp/getting-patients-started "Explore all resources") |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------+
+-------------------------------------------------------+
| Section Metadata |
+-----------------------------------+-------------------+
| backgroundOption | color |
+-----------------------------------+-------------------+
| backgroundColor | background-custom |
+-----------------------------------+-------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+-------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+-------------------+
| textColor | auto |
+-----------------------------------+-------------------+
| additionalPadding | narrow |
+-----------------------------------+-------------------+
| additionalMargin | none |
+-----------------------------------+-------------------+
---
+-----------------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, ctastyle primary, ctacolor light, ctaselection link, ctatarget |
| sametab, ctaexitinterstitial select) |
+-----------------------------------------------------------------------------------------------------------------------+
| ### AUTHORIZATION GUIDE |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+-----------------------------------------------------------+
| Spacer And Divider (divider, medium, contrast, small one) |
+-----------------------------------------------------------+
| |
+-----------------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, title fs 24px, description fs 16px, ctanumber one, ctatype textlink, ctacolor light, ctastyle primary, ctaselection asset, ctatarget sametab, ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Get the Prior Authorization Guide |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| A guide on how to complete a prior authorization. |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| [Download guide](https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:afc23db7-c377-48ec-a0f2-80251447920d/renditions/original/as/CMAT-21629-zepbound-hcp-prior-authorization-resource-guide-digital-04436625.pdf?assetname=CMAT-21629-zepbound-hcp-prior-authorization-resource-guide-digital-04436625.pdf "Read the prior authorization guide to learn more about the appeals process with healthcare providers") |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------+
| Spacer And Divider (spacer, medium, contrast, small one) |
+----------------------------------------------------------+
| |
+----------------------------------------------------------+
+--------------+
| Column Break |
+--------------+
| |
+--------------+
+---------------------------------------------------------------------------------------------------------------+
| Promo Banner (textalign left, highlight color primary, titlestyle ringside, ctastyle primary, ctacolor light, |
| ctaselection link, ctatarget sametab, ctaexitinterstitial select) |
+---------------------------------------------------------------------------------------------------------------+
| ### SAVINGS CARD |
+---------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------+
+-----------------------------------------------------------+
| Spacer And Divider (divider, medium, contrast, small one) |
+-----------------------------------------------------------+
| |
+-----------------------------------------------------------+
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, title fs 24px, ctanumber one, ctatype textlink, ctacolor light, ctastyle primary, ctaselection link, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial |
| select two) |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Share the Zepbound savings card for the Single-Dose Pen |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Download a savings card for your eligible, commercially insured patients with Zepbound coverage.\ |
| \ |
| **Governmental beneficiaries excluded, terms and conditions apply.** [Review full terms and conditions](/savings/terms-and-conditions "Terms and Conditions") |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| [Learn more](/hcp/coverage-savings "Learn more") |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+
+----------------------------------------------------------------+
| Section Metadata |
+-----------------------------------+----------------------------+
| backgroundOption | color |
+-----------------------------------+----------------------------+
| backgroundColor | background-custom |
+-----------------------------------+----------------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+----------------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+----------------------------+
| textColor | auto |
+-----------------------------------+----------------------------+
| style | two-col-50-50, inner-color |
+-----------------------------------+----------------------------+
| additionalPadding | narrow |
+-----------------------------------+----------------------------+
| additionalMargin | none |
+-----------------------------------+----------------------------+
---
+-----------------------+
| Hcp Request Resources |
+-----------------------+
| |
+-----------------------+
+--------------------------------------+
| Section Metadata |
+------------------+-------------------+
| backgroundOption | color |
+------------------+-------------------+
| backgroundColor | background-custom |
+------------------+-------------------+
| textColor | auto |
+------------------+-------------------+
---
+--------------------------------------+
| Section Metadata |
+------------------+-------------------+
| backgroundOption | color |
+------------------+-------------------+
| backgroundColor | background-custom |
+------------------+-------------------+
| textColor | auto |
+------------------+-------------------+
---
+----------------------------------------------------------+
| Spacer And Divider (divider, small, contrast, small one) |
+----------------------------------------------------------+
| |
+----------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, large one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+-----------------------------------------------------------------------------------------------------------------------+
| Two Column With Image (imageplacement left, mediatype icon, textplacement center, title fs 36px, description fs 36px, |
| ctanumber one, ctaplacement left, background color none, ctatype button, ctacolor light, ctastyle primary, |
| ctaselection link, ctatarget sametab, ctaexitinterstitial select, ctatype button two, ctacolor light two, ctastyle |
| primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+-----------------------------------------------------------------------------------------------------------------------+
| ![Pharmacist working in a pharmacy][image16] |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| ### Start your patients on Zepbound |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| [Learn more](/hcp/getting-patients-started "Learn more about starting your patients on Zepbound") |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
| |
+-----------------------------------------------------------------------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, large one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------------------+
| Spacer And Divider (divider, small, contrast, small one) |
+----------------------------------------------------------+
| |
+----------------------------------------------------------+
+-------------------------------------------------------+
| Section Metadata |
+-----------------------------------+-------------------+
| backgroundOption | color |
+-----------------------------------+-------------------+
| backgroundColor | background-custom |
+-----------------------------------+-------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+-------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+-------------------+
| textColor | auto |
+-----------------------------------+-------------------+
| additionalPadding | narrow |
+-----------------------------------+-------------------+
| additionalMargin | none |
+-----------------------------------+-------------------+
---
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, description fs 16px, footnote fs 14px, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, ctaexitinterstitial |
| select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, ctatarget sametab two, ctaexitinterstitial select two) |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **References** |
| |
| 1. Zepbound. Prescribing Information. Lilly USA, LLC. |
| 2. Zepbound. Instructions for Use. Lilly USA, LLC. |
| 3. Maceira E, Lesar TS, Smith HS. Medication related nausea and vomiting in palliative medicine. *Ann Palliat Med*. 2012;1(2):161-176. doi:10.3978/j.issn.2224-5820.2012.07.11 |
| 4. Kruger DF, Bode B, and Spollett GR. Understanding GLP-1 analogs and enhancing patients success. *Diabetes Educ.* 2010;36(suppl 3):S44-S74. doi:10.1177/0145721710374370 |
| 5. Reid TS. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. *Clin Diabetes*. 2013;31(4):148-157. doi:10.2337/diaclin.31.4.148 |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
+-------------------------------------------------------+
| Section Metadata |
+-----------------------------------+-------------------+
| backgroundOption | color |
+-----------------------------------+-------------------+
| backgroundColor | background-custom |
+-----------------------------------+-------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+-------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+-------------------+
| textColor | auto |
+-----------------------------------+-------------------+
| additionalPadding | narrow |
+-----------------------------------+-------------------+
---
+-----------------------------------------------------------------------------------------------------------------------------------------------------------+
| Icontile (columnconfig 2 col) |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------+
| |
+----+-------------------+-----------------+----------------------------+--------------------------------------------------------------------------+---+----+
| | ![Chats][image17] | ### **Call Us** | tile, ctaselection-link, | Dial 1-800-LillyRx\ | | |
| | | | ctatarget-sametab, | [(1-800-545-5979)](tel:1-800-545-5979) to contact Lilly Support Services | | |
| | | | ctaexitinterstitial-select | | | |
+----+-------------------+-----------------+----------------------------+--------------------------------------------------------------------------+---+----+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+---------------------------------------------------------+
| Spacer And Divider (spacer, large, contrast, small one) |
+---------------------------------------------------------+
| |
+---------------------------------------------------------+
+----------------------------------------------------------------------------------------------------------------------------------+
| Text Component (alignment left, ctanumber one, ctatype button, ctacolor light, ctastyle primary, ctatarget sametab, |
| ctaexitinterstitial select, ctaplacement vertical, ctatype button two, ctacolor light two, ctastyle primary two, ctatarget |
| sametab two, ctaexitinterstitial select two) |
+----------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------+
| CMAT-22252 10/2026 **[© Lilly USA, LLC 2026. All rights reserved.](https://lillyhub.com/legal/lillyusa/english/copyright.html)** |
+----------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------------------------------------------------------------+
+--------------------------------------------------------+
| Section Metadata |
+-----------------------------------+--------------------+
| backgroundOption | color |
+-----------------------------------+--------------------+
| backgroundColor | background-premium |
+-----------------------------------+--------------------+
| desktopBackgroundImagePositioning | center center |
+-----------------------------------+--------------------+
| mobileBackgroundImagePositioning | center center |
+-----------------------------------+--------------------+
| textColor | auto |
+-----------------------------------+--------------------+
| additionalPadding | narrow |
+-----------------------------------+--------------------+
+--------------------------------------------------------------------------------------------------------------+
| Metadata |
+------------------+-------------------------------------------------------------------------------------------+
| title | Dosage Options, Schedules & Missed Doses \| Zepbound® (tirzepatide) |
+------------------+-------------------------------------------------------------------------------------------+
| isitype | hcp |
+------------------+-------------------------------------------------------------------------------------------+
| published-time | 2026-11-12T16:28:08.485Z |
+------------------+-------------------------------------------------------------------------------------------+
| description | Zepbound® (tirzepatide) comes in multiple dosage forms including the Zepbound® |
| | single-dose Pen, single-dose Vial, and single-patient-use KwikPen® (4 doses per KwikPen). |
| | Learn about dosing options, how to start and continue Zepbound®, and helpful tips for |
| | patients on Zepbound® . |
+------------------+-------------------------------------------------------------------------------------------+
| canonical | https\://zepbound.lilly.com/hcp/dosage |
+------------------+-------------------------------------------------------------------------------------------+
| content-page-ref | BMYLb8ZHjISE98kDa\_rJwdectoePIJtwjO\_vwXWIJJB6\_wE1aLUtgZ-kqQgnuPWOOcg3KPO4ii9Yp9mWoCnZlQ |
+------------------+-------------------------------------------------------------------------------------------+
| json-ld | { "@context": "https\://schema.org", "@graph": \[ { "@type": \[ |
| | "Organization", "Corporation" ], "@id": |
| | "https\://www\.lilly.com/#organization", "name": "Eli Lilly and Company", |
| | "url": "https\://www\.lilly.com", "telephone": "\+1-317-276-2000", "sameAs": |
| | \[ "https\://www\.linkedin.com/company/eli-lilly-and-company", |
| | "https\://x.com/elilillyandco", "https\://www\.facebook.com/elilillyandco" |
| | ], "logo": { "@type": "ImageObject", "url": |
| | "https\://investor.lilly.com/static-files/414b590d-5fd8-4d74-bb91-284a3d77fb98", |
| | "width": 1391, "height": 981 }, "address": { "@type": |
| | "PostalAddress", "streetAddress": "Lilly Corporate Center", |
| | "addressLocality": "Indianapolis", "addressRegion": "IN", "postalCode": |
| | "46285", "addressCountry": "US" } }, { "@type": |
| | "Organization", "@id": "https\://www\.fda.gov/#org", "name": "U.S. Food and |
| | Drug Administration", "alternateName": "FDA", "url": "https\://www\.fda.gov" |
| | }, { "@type": "WebSite", "@id": |
| | "https\://zepbound.lilly.com/#website", "url": "https\://zepbound.lilly.com", |
| | "name": "Zepbound", "description": "Learn more about Zepbound (tirzepatide) |
| | injection, a weight loss medication for adults with obesity and also for |
| | moderate-to-severe obstructive sleep apnea in adults with obesity.", "inLanguage": |
| | "en-US", "publisher": { "@id": "https\://www\.lilly.com/#organization" |
| | } }, { "@type": "MedicalWebPage", "@id": |
| | "https\://zepbound.lilly.com/hcp/dosage#page", "url": |
| | "https\://zepbound.lilly.com/hcp/dosage", "name": "Dosage Options, Schedules & |
| | Missed Doses \| Zepbound (tirzepatide)", "description": "Zepbound (tirzepatide) |
| | comes in multiple dosage forms including the Zepbound single-dose Pen, single-dose Vial, |
| | and single-patient-use KwikPen (4 doses per KwikPen). Learn about dosing options, how to |
| | start and continue Zepbound, and helpful tips for patients on Zepbound.", |
| | "inLanguage": "en-US", "isPartOf": { "@id": |
| | "https\://zepbound.lilly.com/#website" }, "breadcrumb": { "@id": |
| | "https\://zepbound.lilly.com/hcp/dosage#breadcrumbs" }, "about": { |
| | "@id": "https\://zepbound.lilly.com/#drug" }, "mentions": \[ { |
| | "@id": "https\://zepbound.lilly.com/#approved-indication-weight" }, { |
| | "@id": "https\://zepbound.lilly.com/#approved-indication-osa" }, |
| | { "@id": "https\://zepbound.lilly.com/#condition-obesity" }, { |
| | "@id": "https\://zepbound.lilly.com/#condition-overweight" }, { |
| | "@id": "https\://zepbound.lilly.com/#condition-osa" } ], |
| | "medicalAudience": { "@type": "MedicalAudience", "audienceType": |
| | "Clinician" }, "specialty": \[ { "@id": |
| | "https\://schema.org/Endocrine" }, { "@id": |
| | "https\://schema.org/DietNutrition" }, { "@id": |
| | "https\://schema.org/Pulmonary" } ], "publisher": { "@id": |
| | "https\://www\.lilly.com/#organization" } }, { "@type": |
| | "BreadcrumbList", "@id": "https\://zepbound.lilly.com/hcp/dosage#breadcrumbs", |
| | "itemListElement": \[ { "@type": "ListItem", "position": 1, |
| | "name": "Home", "item": "https\://zepbound.lilly.com" }, |
| | { "@type": "ListItem", "position": 2, "name": "Healthcare |
| | Providers", "item": "https\://zepbound.lilly.com/hcp" }, { |
| | "@type": "ListItem", "position": 3, "name": "Dosage Options, |
| | Schedules & Missed Doses", "item": "https\://zepbound.lilly.com/hcp/dosage" |
| | } ] }, { "@type": "Drug", "@id": |
| | "https\://zepbound.lilly.com/#drug", "name": "Zepbound", "alternateName": |
| | "Zepbound (tirzepatide) injection", "nonProprietaryName": "tirzepatide", |
| | "activeIngredient": "tirzepatide", "drugClass": "glucose-dependent insulinotropic |
| | polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist", |
| | "manufacturer": { "@id": "https\://www\.lilly.com/#organization" }, |
| | "recognizingAuthority": { "@id": "https\://www\.fda.gov/#org" }, |
| | "prescriptionStatus": "https\://schema.org/PrescriptionOnly", "prescribingInfo": |
| | "https\://pi.lilly.com/us/zepbound-uspi.pdf", "administrationRoute": |
| | "Subcutaneous", "dosageForm": \[ "Pre-filled single-dose pen", |
| | "Single-dose vial", "Multi-dose vial", "Single-patient-use KwikPen" |
| | ] }, { "@type": "ApprovedIndication", "@id": |
| | "https\://zepbound.lilly.com/#approved-indication-weight", "name": "To reduce |
| | excess body weight and maintain weight reduction long term in adults with obesity or |
| | adults with overweight in the presence of at least one weight-related comorbid |
| | condition.", "recognizingAuthority": { "@id": "https\://www\.fda.gov/#org" |
| | }, "guideline": { "@type": "MedicalGuideline", "name": |
| | "Zepbound Full Prescribing Information", "url": |
| | "https\://pi.lilly.com/us/zepbound-uspi.pdf" } }, { "@type": |
| | "ApprovedIndication", "@id": |
| | "https\://zepbound.lilly.com/#approved-indication-osa", "name": "To treat moderate |
| | to severe obstructive sleep apnea (OSA) in adults with obesity.", |
| | "recognizingAuthority": { "@id": "https\://www\.fda.gov/#org" }, |
| | "guideline": { "@type": "MedicalGuideline", "name": "Zepbound Full |
| | Prescribing Information", "url": "https\://pi.lilly.com/us/zepbound-uspi.pdf" |
| | } }, { "@type": "MedicalCondition", "@id": |
| | "https\://zepbound.lilly.com/#condition-obesity", "name": "Obesity", "code": |
| | { "@type": "MedicalCode", "codeValue": "E66.9", "codingSystem": |
| | "ICD-10" }, "relevantSpecialty": { "@id": |
| | "https\://schema.org/Endocrine" }, "drug": { "@id": |
| | "https\://zepbound.lilly.com/#drug" } }, { "@type": |
| | "MedicalCondition", "@id": "https\://zepbound.lilly.com/#condition-overweight", |
| | "name": "Overweight", "code": { "@type": "MedicalCode", |
| | "codeValue": "E66.3", "codingSystem": "ICD-10" }, |
| | "relevantSpecialty": { "@id": "https\://schema.org/Endocrine" }, |
| | "drug": { "@id": "https\://zepbound.lilly.com/#drug" } }, { |
| | "@type": "MedicalCondition", "@id": "https\://zepbound.lilly.com/#condition-osa", |
| | "name": "Obstructive sleep apnea", "alternateName": "OSA", "code": { |
| | "@type": "MedicalCode", "codeValue": "G47.33", "codingSystem": |
| | "ICD-10" }, "relevantSpecialty": { "@id": |
| | "https\://schema.org/Pulmonary" }, "drug": { "@id": |
| | "https\://zepbound.lilly.com/#drug" } } ] } |
+------------------+-------------------------------------------------------------------------------------------+
| modified-time | 2026-11-12T16:27:53.789Z |
+------------------+-------------------------------------------------------------------------------------------+
[image0]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:aa9e9e3e-67cd-426b-93c4-860713cae569/as/ZEP_landing_hero_desktop.avif?assetname=ZEP_landing_hero_desktop.png
[image1]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:ffd2d4fa-904e-426c-895a-78656d8738f5/as/ZEP_landing_hero_mobile.avif?assetname=ZEP_landing_hero_mobile.png
[image2]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:3435b828-a9df-431d-a8bf-b7fef73411ba/as/Zepbound_Pen_Tilted_2-5mg_BG.avif?assetname=Zepbound_Pen_Tilted_2-5mg_BG.png
[image3]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:6f9a23c3-585f-41c8-b542-38d032fc7f42/as/LILL_A929396_RGB_Kwikpen_resized.avif?assetname=LILL_A929396_RGB_Kwikpen_resized.png
[image4]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:57025266-e2d6-4dd7-8d91-2385412ea997/as/LILL_A925292_RGB_Vial_resized.avif?assetname=LILL_A925292_RGB_Vial_resized.png
[image5]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:58a14b4d-bd39-40fe-a5e4-cd7a75526e92/as/PMC-AV-80388_ZP_US_OSA_Dosing-IVA-Alt-1-One-Story_EN_email-desktop.avif?assetname=PMC-AV-80388_ZP_US_OSA_Dosing-IVA-Alt-1-One-Story_EN_email-desktop.png
[image6]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:88150528-59ff-4936-8174-36c1707924f1/as/ZP_US_OSA_Dosing-IVA-Alt-1-One-Story_EN_email-mobile.avif?assetname=ZP_US_OSA_Dosing-IVA-Alt-1-One-Story_EN_email-mobile.png
[image7]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:f1cb610c-8ce6-436b-b4f2-bff9e052d474/renditions/original/as/icon_smaller_meals.svg?assetname=icon_smaller_meals.svg
[image8]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:63e49404-00b2-4b9b-ae6a-c55415f42e7c/renditions/original/as/icon_full_stomach.svg?assetname=icon_full_stomach.svg
[image9]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:7247b7f1-e34f-40f3-bcd8-61432c65a6a3/renditions/original/as/icon_no_fatty_food.svg?assetname=icon_no_fatty_food.svg
[image10]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:b60d7f5d-33ce-4298-8192-e0eb413f0af5/renditions/original/as/icon_bland_food.svg?assetname=icon_bland_food.svg
[image11]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:d28e53c9-3b28-4848-962c-b51aed389c12/renditions/original/as/icon_bottle_water.svg?assetname=icon_bottle_water.svg
[image12]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:4c66303e-30b0-4d0d-ae02-5f4a8cdb5a00/renditions/original/as/Medicine.svg?assetname=Medicine.svg
[image13]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:bc1b8ca8-4e97-40d4-89ea-313b6b4095f6/as/zebound-dosing-schedule-v2-rgb-mobile-desktop.avif?assetname=zebound-dosing-schedule-v2-rgb-mobile-desktop.jpg&originalImageWidth=2561&originalImageHeight=586
[image14]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:ab679f56-7ee8-42ce-a4be-7eb16455b240/as/zebound-dosing-schedule-v2-rgb-mobile.avif?assetname=zebound-dosing-schedule-v2-rgb-mobile.jpg&originalImageWidth=1201&originalImageHeight=1243
[image15]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:a09f7ab1-95ca-4570-bd66-85595b1b8c13/renditions/original/as/ShieldWarning.svg?assetname=ShieldWarning.svg
[image16]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:490dc76c-db82-492b-b5b1-b6f46aebd38a/as/Pharmacist_AS414670976.avif?assetname=Pharmacist_AS414670976.jpeg
[image17]: https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:825f5e40-5d22-41c1-afab-57b74fb727f0/renditions/original/as/greenphone_icon.svg?assetname=greenphone_icon.svg
---
## IMPORTANT SAFETY INFORMATION FOR ZEPBOUND® (tirzepatide) INJECTION
[ WARNING: RISK OF THYROID C-CELL TUMORS
In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Zepbound and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Zepbound.
]
CONTRAINDICATIONS
Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Zepbound. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with tirzepatide.
Risk of Thyroid C-cell Tumors
Counsel patients regarding the potential risk for MTC with the use of Zepbound and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Zepbound. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
Severe Gastrointestinal Adverse Reactions
Use of Zepbound has been associated with gastrointestinal adverse reactions, sometimes severe. In a pool of two Zepbound clinical trials (SURMOUNT-1 and SURMOUNT-2), severe gastrointestinal adverse reactions were reported more frequently among patients receiving Zepbound (5 mg 1.7%, 10 mg 2.5%, 15 mg 3.1%) than placebo (1.0%). Similar rates of severe gastrointestinal adverse reactions were observed in Zepbound clinical trials for weight reduction and in Zepbound clinical trials for obstructive sleep apnea (OSA). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. Zepbound is not recommended in patients with severe gastroparesis.
Acute Kidney Injury Due to Volume Depletion
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP‑1 receptor agonists, or Zepbound. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Zepbound that could lead to volume depletion, especially during dosage initiation and escalation of Zepbound.
Acute Gallbladder Disease
Treatment with Zepbound and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease. In a pool of two clinical trials of Zepbound (SURMOUNT-1 and SURMOUNT-2), cholelithiasis was reported in 1.1% of Zepbound-treated patients and 1.0% of placebo-treated patients, cholecystitis was reported in 0.7% of Zepbound-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of Zepbound-treated patients and no placebo-treated patients. Acute gallbladder events were associated with weight reduction. Similar rates of cholelithiasis were reported in Zepbound clinical trials for weight reduction and in Zepbound trials for OSA. If cholecystitis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.
Acute Pancreatitis
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP‑1 receptor agonists, or Zepbound. After initiation of Zepbound, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue Zepbound and initiate appropriate management.
Hypersensitivity Reactions
There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) in patients treated with tirzepatide. In a pool of two Zepbound clinical trials (SURMOUNT-1 and SURMOUNT-2), 0.1% of Zepbound-treated patients had severe hypersensitivity reactions compared to no placebo-treated patients. Similar rates of severe hypersensitivity reactions were observed in Zepbound clinical trials for weight reduction and in Zepbound trials for OSA. If hypersensitivity reactions occur, advise patients to promptly seek medical attention and discontinue use of Zepbound. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in Zepbound. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Zepbound.
Hypoglycemia
Zepbound lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes mellitus and BMI ≥27 kg/m2 (Study 2), hypoglycemia (plasma glucose <54 mg/dL) was reported in 4.2% of Zepbound-treated patients versus 1.3% of placebo-treated patients. In this trial, patients taking Zepbound in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to Zepbound-treated patients not taking a sulfonylurea (2.1%). There is also increased risk of hypoglycemia in patients treated with tirzepatide in combination with insulin. Hypoglycemia has also been associated with Zepbound and GLP-1 receptor agonists in adults without type 2 diabetes mellitus. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. In patients with diabetes mellitus, monitor blood glucose prior to starting Zepbound and during Zepbound treatment. The risk of hypoglycemia may be lowered by a reduction in the dose of insulin or sulfonylurea (or other concomitantly administered insulin secretagogue).
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus
Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
Pulmonary Aspiration During General Anesthesia or Deep Sedation
Zepbound delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Zepbound, including whether modifying preoperative fasting recommendations or temporarily discontinuing Zepbound could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Zepbound.
Never Share a Zepbound® KwikPen® Between Patients
Never share Zepbound KwikPen between patients, even if the pen needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
Most Common Adverse Reactions
The most common adverse reactions reported in ≥5% of patients treated with Zepbound are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease.
Drug Interactions
Zepbound lowers blood glucose. When initiating Zepbound, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia. Zepbound delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with Zepbound. Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with Zepbound.
Pregnancy
Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue Zepbound when a pregnancy is recognized. Available data with tirzepatide in pregnant patients are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Zepbound (tirzepatide) during pregnancy.
Pregnant patients exposed to Zepbound and healthcare providers are encouraged to register by calling 1-844-524-0039 or emailing at MILEregistry@thermofisher.com. To learn more please call or visit https://pregnancyregistry.lilly.com/zepbound.
Lactation
In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose. There are no available data on the effects of tirzepatide on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Zepbound and any potential adverse effects on the breastfed infant from Zepbound or from the underlying maternal condition.
Females and Males of Reproductive Potential
Use of Zepbound may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation with Zepbound and for 4 weeks after each dose escalation.
Pediatric Use
The safety and effectiveness of Zepbound have not been established in pediatric patients.
Zepbound is available as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg injection.
Please see accompanying Prescribing Information, Including Boxed Warning about possible thyroid tumors, including thyroid cancer, and Medication Guide.
Please see Instructions for Use.
ZP HCP ISI 28AUG2026
This site is intended for US healthcare professionals.
CMAT-22245 10/2026 © Lilly USA, LLC 2026. All rights reserved.
Zepbound®, its delivery device base, and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Lilly Support Services™, boundfor™, and Lilly Health™ are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. All rights reserved.
TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.
Other product/company names mentioned herein are the trademarks of their respective owners.
## INDICATIONS
Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity:
to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
to treat moderate-to-severe-obstructive sleep apnea (OSA) in adults with obesity.
Limitations of Use:
Zepbound contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.